API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 4 days · First seen · Last updated

Hanmi Pharm Epe obesity drug development and launch

Overview

Hanmi Pharm has progressed through the clinical and commercial stages of Epe, a domestic GLP-1 class obesity treatment developed using local technology.

During Phase 3 clinical trials in South Korea, the clinical trial specimen analysis institution GCCL supported the development by providing integrated pharmacokinetics analysis and central lab services. GCCL managed specimen collection, transport, storage, and analysis across approximately 30 domestic clinical institutions to ensure accuracy.

Following domestic approval in October 2026, Hanmi Pharm officially commenced domestic sales activities for Epe. The company held a large-scale launch event in Daejeon to mark the product, which was developed using the proprietary Labscovery platform technology. Hanmi Pharm intends to implement a Total Lifestyle Care strategy, combining pharmacological treatment with dietary and exercise management.

Entities

Hanmi Pharm · EPE · Hwang Sang-yeon · GCCL · Daejeon

Timeline

  1. [BUSINESS] 3 sources
    Hanmi Pharm launches Epe, a domestic GLP-1 obesity drug

    Hanmi Pharm has launched Epe, a domestically developed GLP-1 obesity treatment, initiating large-scale sales and marketing efforts in South Korea.

  2. [BUSINESS] 2 sources
    GCCL supports Hanmi Pharm in development of domestic obesity drug Epe

    GCCL provided pharmacokinetics analysis and central lab services for Hanmi Pharm’s Phase 3 trials of Epe, South Korea’s first domestically developed GLP-1 obesity drug.

Sources

bosa.co.kr · hin.company · linkmagazine.nl · thebionews.net